AI Policy Wiki
Dashboard

Eric Topol

medium confidence · updated 2026-06-06

Cardiologist, Scripps Research Translational Institute founder/director, author of Deep Medicine. Sustained skeptic of LLM clinical-outcome claims; argued in May 2026 that there is 'very little evidence for LLMs benefiting patients or doctors for health outcomes' outside administrative work.

Eric Topol is a cardiologist and the founder and director of the Scripps Research Translational Institute. He is the author of Deep Medicine (2019) and Super Agers (2024), and writes a long-running Substack, Ground Truths, on AI in medicine. He has argued that there is little empirical evidence that large language models improve patient health outcomes outside administrative tasks.

Background and roles

Topol is a cardiologist and founder and director of the Scripps Research Translational Institute. His books include Deep Medicine (2019) and Super Agers (2024), and he publishes the Ground Truths Substack on AI in medicine.

Positions on AI in medicine

Topol's position on whether LLMs improve patient outcomes, set out in a May 3, 2026 review, is that the empirical case is thin. He wrote that there is "very little evidence for LLMs benefiting patients or doctors for health outcomes" outside administrative work such as clinical-note drafting, prior-authorization paperwork, and insurance-coding workflows (Topol/Marcus: LLMs and Patient Outcomes — three-document cluster; Source: open.substack.com).

Gary Marcus took the same position the same day, citing a Nature Medicine editorial making the same point in stronger institutional language (Source: garymarcus.substack.com). Topol and Marcus frame the industry-communications claim that "AI will revolutionize healthcare" as outpacing the clinical-outcome evidence base.

Topol's skepticism is specific to LLMs producing patient-outcome improvements rather than categorical opposition to AI in medicine; he has long advocated for AI in pattern-recognition tasks such as imaging and ECG analysis. He acknowledges productivity gains in non-clinical administrative tasks but argues that, under current evidence, those gains do not translate into improved diagnosis, treatment, or survival. He argues that randomized trials, rather than anecdotal deployments, should set the bar for clinical claims.

Topol's review is paired methodologically with the Lancet endoscopist-deskilling study, which documents an adverse outcome of AI assistance, as counter-evidence to optimistic deployment narratives in clinical settings.

Sources

Relationships